Skip to main content

Specialty Pharmacy

  • Tech, interconnectivity focus of NCPDP summit

    Technology is not only bringing more benefits to patients in the pharmacy, but it’s also offering them a host of products so they can be more involved in their health care. This was a theme at the National Council for Prescription Drug Programs’ educational summit, “Leveraging New Technologies: Impact on the Patient and the Healthcare Industry,” on Feb. 8 in Las Vegas.


  • BP kiosk uploads data to EHR

    ROCHESTER, N.Y. — Blood-pressure kiosks have become a ubiquitous site in retail pharmacies across the country, but like pharmacy automation and technology as a whole, they’re continuing to advance and offer new features.

  • Sean Whelan named Diplomat's new CFO

    FLINT, Mich. — Diplomat Specialty Pharmacy has hired a new CFO, the company said.

    Diplomat announced the appointment of Sean Whelan, citing his experience as a CFO in the healthcare industry. Whelan will report directly to president and CEO Phil Hagerman.

  • Savient announces executive appointments

    EAST BRUNSWICK, N.J. — Savient Pharmaceuticals announced changes to its management team as it gears up for the commercial launch of its chronic gout treatment.

    The drug maker appointed Louis Ferrari as its SVP corporate development, Christine Mikail as SVP and Stephen Davies as chief information officer and group VP.

  • Report: Exclusivity period for biotech drugs may be reduced to seven years

    WASHINGTON — The Obama administration’s proposed budget for 2012 contains an item that could change the game for biosimilars, according to published reports.

    According to the reports, the administration would lower the 12-year data exclusivity period for biotech drugs mandated in the healthcare-reform law to seven years.

  • Amicus' Amigal improves symptoms among Fabry disease patients in trial

    CRANBURY, N.J. — Amicus Therapeutics received good results from its mid-stage trial of a drug for a rare, genetic disorder, the drug maker said Wednesday.

  • Sanofi-Aventis obtains Genzyme for $20.1 billion

    CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

  • Gilead resubmits HIV drug application to FDA

    FOSTER CITY, Calif. — Gilead Sciences has refiled an approval application with the Food and Drug Administration for an HIV drug, the drug maker said.

    Gilead said it had resubmitted its application for a single-tablet combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Johnson & Johnson subsidiary Tibotec Pharmaceuticals’ investigational drug TMC278 (rilpivirine hydrochloride) to treat HIV-1 infection in adults.

X
This ad will auto-close in 10 seconds